Abcam plc (ABC.L)
| Previous close | 1,168.00 |
| Open | 1,192.00 |
| Bid | 1,179.00 x 0 |
| Ask | 1,180.00 x 0 |
| Day's range | 1,173.00 - 1,203.00 |
| 52-week range | 11.05 - 1,780.00 |
| Volume | |
| Avg. volume | 312,604 |
| Market cap | 2.699B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 620.53 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 19 Mar 2020 |
| 1y target est | N/A |
- Business Wire
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
CAMBRIDGE, England & SOUTH SAN FRANCISCO, Calif., February 01, 2022--Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic an
- Globe Newswire
29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases
CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December1, therefore these interim financial statements report on both a six- and 12-month period. SUMMARY PERFORMANCE 12 mont
- Globe Newswire
Abcam to Acquire BioVision for $340 million
CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). Transaction highlights BioVision is a fast-growing innovator and distributor of life
